Artificial intelligence is no longer a side project in the pharmaceutical world. Two recent reports suggest it is becoming part of how medicines get made — and how health systems decide whether AI tools are safe enough to use on patients.
The Daily Star, in a piece headlined "How AI is changing the pharmaceuticals landscape," frames the technology as reshaping the industry rather than merely assisting it. That framing matters because pharma has historically been one of the slowest sectors to adopt new computational methods, constrained by regulation, long development timelines, and the sheer cost of getting a drug wrong.
Separately, Ynetnews reports that the World Health Organization has highlighted the AI safety model developed by Clalit — the Israeli health services organization — as a global benchmark for healthcare. In practice, a "safety model" is the governance layer: the rules and checks that determine how an AI system is validated, monitored, and permitted to influence clinical decisions. WHO endorsement of one organization's approach signals that international bodies are trying to establish shared standards rather than letting each hospital and drugmaker invent their own.
Read together, the two items describe the same shift from opposite ends. One is about capability — AI changing how drugs are discovered and developed. The other is about guardrails — how the world agrees to keep those systems accountable. Historically, capability has raced ahead while governance lagged; the WHO's attention to Clalit's model suggests regulators are trying to close that gap while the technology is still taking shape.
Neither source, as summarized here, provides specific figures on approved drugs, trial outcomes, or investment totals, so the practical scale of AI's impact on medicine remains an open question.
It matters because drugs that reach patients faster and safer depend on both halves working: the tools that find new molecules, and the standards that decide when to trust them.